Last 12 months
Inside the activity.
0 purchase rows · 13 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 4 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 05, 2020 Filed Mar 5, 2020 21:18 UTC |
Mickle Travis CDirector · President & CEO
|
PurchaseCommon Stock | 2,500 | $0.33 | $824.50 |
DisclosureSEC source: 0001437749-20-004438 · rdgdoc.xml · nonDerivative · entry 7 Mickle Travis C · CIK 0001638365 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,778,117 Read SEC document |
| March 05, 2020 Filed Mar 5, 2020 21:18 UTC |
Mickle Travis CDirector · President & CEO
|
PurchaseCommon Stock | 4,500 | $0.33 | $1,484.10 |
DisclosureSEC source: 0001437749-20-004438 · rdgdoc.xml · nonDerivative · entry 6 Mickle Travis C · CIK 0001638365 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,775,617 Read SEC document |
| March 05, 2020 Filed Mar 5, 2020 21:18 UTC |
Mickle Travis CDirector · President & CEO
|
PurchaseCommon Stock | 3,000 | $0.33 | $989.70 |
DisclosureSEC source: 0001437749-20-004438 · rdgdoc.xml · nonDerivative · entry 5 Mickle Travis C · CIK 0001638365 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,771,117 Read SEC document |
| March 05, 2020 Filed Mar 5, 2020 21:18 UTC |
Mickle Travis CDirector · President & CEO
|
PurchaseCommon Stock | 4,500 | $0.33 | $1,501.65 |
DisclosureSEC source: 0001437749-20-004438 · rdgdoc.xml · nonDerivative · entry 4 Mickle Travis C · CIK 0001638365 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,768,117 Read SEC document |
| March 05, 2020 Filed Mar 5, 2020 21:18 UTC |
Mickle Travis CDirector · President & CEO
|
PurchaseCommon Stock | 4,500 | $0.33 | $1,498.50 |
DisclosureSEC source: 0001437749-20-004438 · rdgdoc.xml · nonDerivative · entry 3 Mickle Travis C · CIK 0001638365 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,763,617 Read SEC document |
| March 05, 2020 Filed Mar 5, 2020 21:18 UTC |
Mickle Travis CDirector · President & CEO
|
PurchaseCommon Stock | 3,000 | $0.33 | $1,002.30 |
DisclosureSEC source: 0001437749-20-004438 · rdgdoc.xml · nonDerivative · entry 2 Mickle Travis C · CIK 0001638365 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,759,117 Read SEC document |
| March 05, 2020 Filed Mar 5, 2020 21:18 UTC |
Mickle Travis CDirector · President & CEO
|
PurchaseCommon Stock | 3,000 | $0.33 | $1,003.20 |
DisclosureSEC source: 0001437749-20-004438 · rdgdoc.xml · nonDerivative · entry 1 Mickle Travis C · CIK 0001638365 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,756,117 Read SEC document |
| February 05, 2020 Filed Feb 8, 2020 02:38 UTC |
Sangiovanni Timothy J.VP, Corporate Controller
|
GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001437749-20-002098 · rdgdoc.xml · derivative · entry 1 Sangiovanni Timothy J. · CIK 0001698328 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-02-04 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2014 Equity Incentive Plan (the "Plan"). 50% of the shares underlying the option will vest upon the approval by the U.S. Food and Drug Administration of a new drug application for the Company's product candidate, KP415. The remaining 50% of the shares underlying the option will vest upon the approval of a label for KP415 which includes 30 minute onset and 13-hour duration (the "30/13 Label") as defined in the KP415 License Agreement dated September 3, 2019. Each vesting event is contingent upon such optionee's continued employment with the Issuer at the relevant vesting date as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:38 UTC |
Clifton R. LaDuaneCFO, Secretary & Treasurer
|
GrantStock Option (right to buy) · Derivative | 160,000 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001437749-20-002097 · rdgdoc.xml · derivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2030-02-04 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2014 Equity Incentive Plan (the "Plan"). 50% of the shares underlying the option will vest upon the approval by the U.S. Food and Drug Administration of a new drug application for the Company's product candidate, KP415. The remaining 50% of the shares underlying the option will vest upon the approval of a label for KP415 which includes 30 minute onset and 13-hour duration (the "30/13 Label") as defined in the KP415 License Agreement dated September 3, 2019. Each vesting event is contingent upon such optionee's continued employment with the Issuer at the relevant vesting date as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| February 05, 2020 Filed Feb 8, 2020 02:39 UTC |
Guenther SvenEVP, Research & Development
|
GrantStock Option (right to buy) · Derivative | 160,000 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001437749-20-002100 · rdgdoc.xml · derivative · entry 1 Guenther Sven · CIK 0001638368 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2030-02-04 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2014 Equity Incentive Plan (the "Plan"). 50% of the shares underlying the option will vest upon the approval by the U.S. Food and Drug Administration of a new drug application for the Company's product candidate, KP415. The remaining 50% of the shares underlying the option will vest upon the approval of a label for KP415 which includes 30 minute onset and 13-hour duration (the "30/13 Label") as defined in the KP415 License Agreement dated September 3, 2019. Each vesting event is contingent upon such optionee's continued employment with the Issuer at the relevant vesting date as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| February 05, 2020 Filed Feb 8, 2020 02:38 UTC |
Mickle Travis CDirector · President & CEO · 10% owner
|
GrantStock Option (right to buy) · Derivative | 420,000 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001437749-20-002099 · rdgdoc.xml · derivative · entry 1 Mickle Travis C · CIK 0001638365 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 420,000 Underlying: Common Stock · 420,000 shares Expires 2030-02-04 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2014 Equity Incentive Plan (the "Plan"). 50% of the shares underlying the option will vest upon the approval by the U.S. Food and Drug Administration of a new drug application for the Company's product candidate, KP415. The remaining 50% of the shares underlying the option will vest upon the approval of a label for KP415 which includes 30 minute onset and 13-hour duration (the "30/13 Label") as defined in the KP415 License Agreement dated September 3, 2019. Each vesting event is contingent upon such optionee's continued employment with the Issuer at the relevant vesting date as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 21:45 UTC |
Johnson Gordon KChief Business Officer
|
PurchaseCommon Stock | 10,000 | $0.39 | $3,884.00 |
DisclosureSEC source: 0001437749-20-000071 · rdgdoc.xml · nonDerivative · entry 2 Johnson Gordon K · CIK 0001638367 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 21:45 UTC |
Johnson Gordon KChief Business Officer
|
PurchaseCommon Stock | 10,000 | $0.39 | $3,900.00 |
DisclosureSEC source: 0001437749-20-000071 · rdgdoc.xml · nonDerivative · entry 1 Johnson Gordon K · CIK 0001638367 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Read SEC document |
| December 27, 2019 Filed Dec 30, 2019 16:26 UTC |
Clifton R. LaDuaneCFO, Secretary & Treasurer
|
PurchaseCommon Stock | 2,250 | $0.42 | $937.58 |
DisclosureSEC source: 0001437749-19-025002 · rdgdoc.xml · nonDerivative · entry 3 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Read SEC document |
| December 27, 2019 Filed Dec 30, 2019 16:26 UTC |
Clifton R. LaDuaneCFO, Secretary & Treasurer
|
PurchaseCommon Stock | 5,000 | $0.42 | $2,087.50 |
DisclosureSEC source: 0001437749-19-025002 · rdgdoc.xml · nonDerivative · entry 2 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,750 Read SEC document |
| December 27, 2019 Filed Dec 30, 2019 16:26 UTC |
Clifton R. LaDuaneCFO, Secretary & Treasurer
|
PurchaseCommon Stock | 5,000 | $0.42 | $2,084.50 |
DisclosureSEC source: 0001437749-19-025002 · rdgdoc.xml · nonDerivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,750 Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 16:15 UTC |
Clifton R. LaDuaneCFO, Secretary & Treasurer
|
GrantStock Option (right to buy) · Derivative | 36,000 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001437749-19-023642 · rdgdoc.xml · derivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2029-11-24 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2014 Equity Incentive Plan (the "Plan"). 100% of the shares underlying the option will vest upon the acceptance of a new drug application for the Company's product candidate, KP415, by the U.S. Food and Drug Administration, provided that at the relevant vesting date such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 21:15 UTC |
Guenther SvenEVP, Research & Development
|
GrantStock Option (right to buy) · Derivative | 56,000 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001437749-19-023646 · rdgdoc.xml · derivative · entry 1 Guenther Sven · CIK 0001638368 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,000 Underlying: Common Stock · 56,000 shares Expires 2029-11-24 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2014 Equity Incentive Plan (the "Plan"). 100% of the shares underlying the option will vest upon the acceptance of a new drug application for the Company's product candidate, KP415, by the U.S. Food and Drug Administration, provided that at the relevant vesting date such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 21:15 UTC |
Johnson Gordon KChief Business Officer
|
GrantStock Option (right to buy) · Derivative | 36,000 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001437749-19-023645 · rdgdoc.xml · derivative · entry 1 Johnson Gordon K · CIK 0001638367 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2029-11-24 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2014 Equity Incentive Plan (the "Plan"). 100% of the shares underlying the option will vest upon the acceptance of a new drug application for the Company's product candidate, KP415, by the U.S. Food and Drug Administration, provided that at the relevant vesting date such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 21:15 UTC |
Sangiovanni Timothy J.VP, Corporate Controller
|
GrantStock Option (right to buy) · Derivative | 36,000 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001437749-19-023643 · rdgdoc.xml · derivative · entry 1 Sangiovanni Timothy J. · CIK 0001698328 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2029-11-24 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2014 Equity Incentive Plan (the "Plan"). 100% of the shares underlying the option will vest upon the acceptance of a new drug application for the Company's product candidate, KP415, by the U.S. Food and Drug Administration, provided that at the relevant vesting date such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 21:14 UTC |
Mickle Travis CDirector · President & CEO · 10% owner
|
GrantStock Option (right to buy) · Derivative | 36,000 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001437749-19-023640 · rdgdoc.xml · derivative · entry 1 Mickle Travis C · CIK 0001638365 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2029-11-24 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2014 Equity Incentive Plan (the "Plan"). 100% of the shares underlying the option will vest upon the acceptance of a new drug application for the Company's product candidate, KP415, by the U.S. Food and Drug Administration, provided that at the relevant vesting date such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| September 25, 2019 Filed Sep 25, 2019 20:58 UTC |
Clifton R. LaDuaneCFO, Secretary & Treasurer
|
PurchaseCommon Stock | 3,650 | $0.75 | $2,719.98 |
DisclosureSEC source: 0001437749-19-019061 · rdgdoc.xml · nonDerivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,750 Read SEC document |
| September 24, 2019 Filed Sep 25, 2019 00:25 UTC |
Mickle Travis CDirector · President & CEO · 10% owner
|
PurchaseCommon Stock | 5,000 | $0.79 | $3,938.00 |
DisclosureSEC source: 0001437749-19-018999 · rdgdoc.xml · nonDerivative · entry 7 Mickle Travis C · CIK 0001638365 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,753,117 Read SEC document |
| September 24, 2019 Filed Sep 25, 2019 00:25 UTC |
Mickle Travis CDirector · President & CEO · 10% owner
|
PurchaseCommon Stock | 5,000 | $0.78 | $3,919.00 |
DisclosureSEC source: 0001437749-19-018999 · rdgdoc.xml · nonDerivative · entry 6 Mickle Travis C · CIK 0001638365 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,748,117 Read SEC document |
| September 24, 2019 Filed Sep 25, 2019 00:25 UTC |
Mickle Travis CDirector · President & CEO · 10% owner
|
PurchaseCommon Stock | 5,000 | $0.79 | $3,939.00 |
DisclosureSEC source: 0001437749-19-018999 · rdgdoc.xml · nonDerivative · entry 5 Mickle Travis C · CIK 0001638365 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,743,117 Read SEC document |
| September 24, 2019 Filed Sep 25, 2019 00:25 UTC |
Mickle Travis CDirector · President & CEO · 10% owner
|
PurchaseCommon Stock | 5,000 | $0.80 | $3,976.50 |
DisclosureSEC source: 0001437749-19-018999 · rdgdoc.xml · nonDerivative · entry 4 Mickle Travis C · CIK 0001638365 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,738,117 Read SEC document |
| September 24, 2019 Filed Sep 25, 2019 00:25 UTC |
Mickle Travis CDirector · President & CEO · 10% owner
|
PurchaseCommon Stock | 15,000 | $0.79 | $11,848.50 |
DisclosureSEC source: 0001437749-19-018999 · rdgdoc.xml · nonDerivative · entry 3 Mickle Travis C · CIK 0001638365 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,733,117 Read SEC document |
| September 24, 2019 Filed Sep 25, 2019 00:25 UTC |
Mickle Travis CDirector · President & CEO · 10% owner
|
PurchaseCommon Stock | 5,000 | $0.78 | $3,921.50 |
DisclosureSEC source: 0001437749-19-018999 · rdgdoc.xml · nonDerivative · entry 2 Mickle Travis C · CIK 0001638365 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,718,117 Read SEC document |
| September 24, 2019 Filed Sep 25, 2019 00:25 UTC |
Mickle Travis CDirector · President & CEO · 10% owner
|
PurchaseCommon Stock | 10,000 | $0.78 | $7,839.00 |
DisclosureSEC source: 0001437749-19-018999 · rdgdoc.xml · nonDerivative · entry 1 Mickle Travis C · CIK 0001638365 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,713,117 Read SEC document |
| September 24, 2019 Filed Sep 26, 2019 00:57 UTC |
Sangiovanni Timothy J.VP, Corporate Controller
|
PurchaseCommon Stock | 3,000 | $0.74 | $2,220.00 |
DisclosureSEC source: 0001437749-19-019060 · rdgdoc.xml · nonDerivative · entry 1 Sangiovanni Timothy J. · CIK 0001698328 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Read SEC document |
| September 16, 2019 Filed Sep 16, 2019 16:59 UTC |
Clifton R. LaDuaneCFO, Secretary & Treasurer
|
PurchaseCommon Stock | 4,900 | $0.89 | $4,339.44 |
DisclosureSEC source: 0001437749-19-018489 · rdgdoc.xml · nonDerivative · entry 2 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,100 Read SEC document |
| September 16, 2019 Filed Sep 16, 2019 16:59 UTC |
Clifton R. LaDuaneCFO, Secretary & Treasurer
|
PurchaseCommon Stock | 100 | $0.86 | $86.00 |
DisclosureSEC source: 0001437749-19-018489 · rdgdoc.xml · nonDerivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,200 Read SEC document |
| September 11, 2019 Filed Sep 11, 2019 16:50 UTC |
Clifton R. LaDuaneCFO, Secretary & Treasurer
|
PurchaseCommon Stock | 500 | $0.95 | $472.60 |
DisclosureSEC source: 0001437749-19-018218 · rdgdoc.xml · nonDerivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,100 Read SEC document |
| September 09, 2019 Filed Sep 9, 2019 20:12 UTC |
Johnson Gordon KChief Business Officer
|
PurchaseCommon Stock | 5,000 | $0.83 | $4,125.50 |
DisclosureSEC source: 0001437749-19-018071 · rdgdoc.xml · nonDerivative · entry 3 Johnson Gordon K · CIK 0001638367 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
| September 09, 2019 Filed Sep 9, 2019 20:12 UTC |
Johnson Gordon KChief Business Officer
|
PurchaseCommon Stock | 3,000 | $0.80 | $2,409.60 |
DisclosureSEC source: 0001437749-19-018071 · rdgdoc.xml · nonDerivative · entry 2 Johnson Gordon K · CIK 0001638367 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Read SEC document |
| September 09, 2019 Filed Sep 9, 2019 20:12 UTC |
Johnson Gordon KChief Business Officer
|
PurchaseCommon Stock | 2,000 | $0.82 | $1,633.00 |
DisclosureSEC source: 0001437749-19-018071 · rdgdoc.xml · nonDerivative · entry 1 Johnson Gordon K · CIK 0001638367 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Read SEC document |
| September 06, 2019 Filed Sep 6, 2019 17:06 UTC |
Clifton R. LaDuaneCFO, Secretary & Treasurer
|
PurchaseCommon Stock | 850 | $0.77 | $652.29 |
DisclosureSEC source: 0001437749-19-018003 · rdgdoc.xml · nonDerivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,600 Read SEC document |
| June 30, 2019 Filed Jul 2, 2019 21:03 UTC |
Pascoe Richard WDirector
|
GrantCommon Stock | 8,928 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-013390 · rdgdoc.xml · nonDerivative · entry 1 Pascoe Richard W · CIK 0001343266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,573 F1 · shares: Grant to the Reporting Person of a fully vested restricted stock award ("RSA") under the Issuer's 2014 Equity Incentive Plan. The RSA was granted to the Reporting Person in lieu of the quarterly cash compensation payable to the Reporting Person pursuant to the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy. Read SEC document |
| June 30, 2019 Filed Jul 2, 2019 21:04 UTC |
Thompson Danny LDirector
|
GrantCommon Stock | 8,214 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-013394 · rdgdoc.xml · nonDerivative · entry 1 Thompson Danny L · CIK 0001638363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,727 F1 · shares: Grant to the Reporting Person of a fully vested restricted stock award ("RSA") under the Issuer's 2014 Equity Incentive Plan. The RSA was granted to the Reporting Person in lieu of the quarterly cash compensation payable to the Reporting Person pursuant to the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy. Read SEC document |
| June 30, 2019 Filed Jul 2, 2019 21:04 UTC |
Tierney David SDirector
|
GrantCommon Stock | 6,428 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-013393 · rdgdoc.xml · nonDerivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,372 F1 · shares: Grant to the Reporting Person of a fully vested restricted stock award ("RSA") under the Issuer's 2014 Equity Incentive Plan. The RSA was granted to the Reporting Person in lieu of the quarterly cash compensation payable to the Reporting Person pursuant to the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy. Read SEC document |
| June 30, 2019 Filed Jul 2, 2019 21:04 UTC |
Saluri JosephDirector
|
GrantCommon Stock | 7,857 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-013392 · rdgdoc.xml · nonDerivative · entry 1 Saluri Joseph · CIK 0001512131 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,899 F1 · shares: Grant to the Reporting Person of a fully vested restricted stock award ("RSA") under the Issuer's 2014 Equity Incentive Plan. The RSA was granted to the Reporting Person in lieu of the quarterly cash compensation payable to the Reporting Person pursuant to the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy. Read SEC document |
| June 30, 2019 Filed Jul 2, 2019 21:03 UTC |
Plooster Matthew RDirector
|
GrantCommon Stock | 7,857 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-013391 · rdgdoc.xml · nonDerivative · entry 1 Plooster Matthew R · CIK 0001638364 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,512 F1 · shares: Grant to the Reporting Person of a fully vested restricted stock award ("RSA") under the Issuer's 2014 Equity Incentive Plan. The RSA was granted to the Reporting Person in lieu of the quarterly cash compensation payable to the Reporting Person pursuant to the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy. Read SEC document |
| May 10, 2019 Filed May 15, 2019 00:39 UTC |
Saluri JosephDirector
|
GrantCommon Stock | 8,487 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-009882 · rdgdoc.xml · nonDerivative · entry 1 Saluri Joseph · CIK 0001512131 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,042 F1 · shares: Grant to the Reporting Person of a fully vested restricted stock award ("RSA") under the Issuer's 2014 Equity Incentive Plan. The RSA was granted to the Reporting Person in lieu of the quarterly cash compensation payable to the Reporting Person pursuant to the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy. Read SEC document |
| May 10, 2019 Filed May 15, 2019 00:39 UTC |
Pascoe Richard WDirector
|
GrantCommon Stock | 9,645 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-009884 · rdgdoc.xml · nonDerivative · entry 1 Pascoe Richard W · CIK 0001343266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,645 F1 · shares: Grant to the Reporting Person of a fully vested restricted stock award ("RSA") under the Issuer's 2014 Equity Incentive Plan. The RSA was granted to the Reporting Person in lieu of the quarterly cash compensation payable to the Reporting Person pursuant to the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy. Read SEC document |
| May 10, 2019 Filed May 15, 2019 00:39 UTC |
Thompson Danny LDirector
|
GrantCommon Stock | 8,873 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-009883 · rdgdoc.xml · nonDerivative · entry 1 Thompson Danny L · CIK 0001638363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,513 F1 · shares: Grant to the Reporting Person of a fully vested restricted stock award ("RSA") under the Issuer's 2014 Equity Incentive Plan. The RSA was granted to the Reporting Person in lieu of the quarterly cash compensation payable to the Reporting Person pursuant to the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy. Read SEC document |
| May 10, 2019 Filed May 15, 2019 00:39 UTC |
Tierney David SDirector
|
GrantCommon Stock | 6,944 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-009881 · rdgdoc.xml · nonDerivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,944 F1 · shares: Grant to the Reporting Person of a fully vested restricted stock award ("RSA") under the Issuer's 2014 Equity Incentive Plan. The RSA was granted to the Reporting Person in lieu of the quarterly cash compensation payable to the Reporting Person pursuant to the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy. Read SEC document |
| May 10, 2019 Filed May 15, 2019 00:38 UTC |
Plooster Matthew RDirector
|
GrantCommon Stock | 8,487 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-009880 · rdgdoc.xml · nonDerivative · entry 1 Plooster Matthew R · CIK 0001638364 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,655 F1 · shares: Grant to the Reporting Person of a fully vested restricted stock award ("RSA") under the Issuer's 2014 Equity Incentive Plan. The RSA was granted to the Reporting Person in lieu of the quarterly cash compensation payable to the Reporting Person pursuant to the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy. Read SEC document |
| April 24, 2019 Filed Apr 26, 2019 21:01 UTC |
Plooster Matthew RDirector
|
GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001437749-19-008064 · rdgdoc.xml · derivative · entry 1 Plooster Matthew R · CIK 0001638364 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-04-23 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Market on the date of grant, April 24, 2019. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's third amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| April 24, 2019 Filed Apr 26, 2019 21:01 UTC |
Thompson Danny LDirector
|
GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001437749-19-008065 · rdgdoc.xml · derivative · entry 1 Thompson Danny L · CIK 0001638363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-04-23 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Market on the date of grant, April 24, 2019. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's third amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| April 24, 2019 Filed Apr 26, 2019 21:06 UTC |
Saluri JosephDirector
|
GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001437749-19-008070 · rdgdoc.xml · derivative · entry 1 Saluri Joseph · CIK 0001512131 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-04-23 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Market on the date of grant, April 24, 2019. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's third amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.